![[Valid RSS]](images/valid-rss-rogers.png "Valid RSS")
This is a valid RSS feed.
This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.
line 122, column 0: (4 occurrences) [help]
line 256, column 0: (10 occurrences) [help]
line 594, column 0: (2 occurrences) [help]
<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:media="http://search.yahoo.com/mrss/" > <channel> <title>International Biopharmaceutical Industry</title> <atom:link href="https://international-biopharma.com/feed/" rel="self" type="application/rss+xml" /> <link>https://international-biopharma.com</link> <description>Supporting Modern Science Through Communication</description> <lastBuildDate>Fri, 24 Oct 2025 09:21:36 +0000</lastBuildDate> <language>en-GB</language> <sy:updatePeriod> hourly </sy:updatePeriod> <sy:updateFrequency> 1 </sy:updateFrequency> <generator>https://wordpress.org/?v=6.8.3</generator> <image> <url>https://international-biopharma.com/wp-content/uploads/2021/03/IBI-150x150.jpg</url> <title>International Biopharmaceutical Industry</title> <link>https://international-biopharma.com</link> <width>32</width> <height>32</height></image> <item> <title>IMCD showcases greener, smarter, patient-centric solutions at CPHI Frankfurt 2025</title> <link>https://international-biopharma.com/imcd-showcases-greener-smarter-patient-centric-solutions-at-cphi-frankfurt-2025/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Fri, 24 Oct 2025 09:21:34 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=18205</guid> <description><![CDATA[IMCD Group (“IMCD” or “Company”), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, will exhibit at CPHI Frankfurt 2025 from 28 to 30 October, where its experts will unveil a portfolio of greener, smarter, patient-centric solutions designed to meet the evolving demands of the pharmaceutical industry. At this year’s event, IMCD will highlight how […]]]></description> <content:encoded><![CDATA[<p>IMCD Group (“IMCD” or “Company”), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, will exhibit at CPHI Frankfurt 2025 from 28 to 30 October, where its experts will unveil a portfolio of greener, smarter, patient-centric solutions designed to meet the evolving demands of the pharmaceutical industry.</p> <p>At this year’s event, IMCD will highlight how its technical expertise, sustainable innovation, and collaborative approach are helping customers accelerate development and deliver better outcomes for patients.</p> <p>Showcasing a curated selection of formulations, these concepts deliver tangible solutions to the pressing challenges in pharmaceutical development today. Concepts at the booth will sit under three key themes:</p> <ul class="wp-block-list"><li><strong>Greener</strong>: Solutions that deliver sustainability across the pharmaceutical value chain. From sourcing eco-friendly excipients to promoting energy-efficient manufacturing processes. These concepts reduce environmental impact without compromising performance.</li></ul> <ul class="wp-block-list"><li><strong>Smarter</strong>: Leveraging its global network of technical centres and formulation experts, IMCD delivers intelligent solutions that solve complex challenges – including solubility enhancement, modified release, and taste masking. Attendees will discover innovative prototypes such as dual-layer tablets, high-load capsules, and advanced coating systems.</li></ul> <ul class="wp-block-list"><li><strong>Patient-centric</strong>: Formulation concepts designed with the end-user in mind. Whether it’s improving compliance through palatable paediatric formats or enhancing bioavailability for chronic therapies, IMCD will showcase patient-focused solutions that are safer, more effective, and easier to take.</li></ul> <p>At the booth, IMCD experts will present <strong>six innovative concepts</strong>, each demonstrating the company’s ability to combine regulatory insight with formulation excellence to support the rapid development of high-value therapies:</p> <ul class="wp-block-list"><li><strong>Apixaban coated tablet</strong> – A more sustainable alternative to traditional roller compaction. The direct compression formulation reduces manufacturing steps, energy use, and cleaning, while maintaining comparable performance to the originator.</li></ul> <ul class="wp-block-list"><li><strong>Apremilast ointment</strong> – A novel, more patient-friendly topical treatment concept for psoriasis that enhances API solubility and skin permeation, offering a non-greasy, easy-to-apply formulation free from the side effects of oral therapy.</li></ul> <ul class="wp-block-list"><li><strong>Caffeine SR effervescent tablet</strong> – A dual-release concept combining immediate and sustained caffeine delivery for long-lasting energy without the “crash,” with taste masking and effervescent convenience that promote hydration and compliance.</li></ul> <ul class="wp-block-list"><li><strong>Ginkgo coated tablet</strong> – A direct compression, once-a-day liposomal ginkgo biloba tablet that improves absorption, ensures stability, and delivers performance in a small, easy-to-swallow format.</li></ul> <ul class="wp-block-list"><li><strong>Terbinafine film forming solution</strong> – A transparent, water-resistant film that provides prolonged antifungal action with a pleasant, non-tacky feel, for an advanced, patient-friendly approach to treating athlete’s foot.</li></ul> <ul class="wp-block-list"><li><strong>Mucoadhesive gel platform</strong> – A versatile platform for targeted, patient-centric drug delivery across oral, buccal, vaginal, and other mucosal routes, extending retention time and offering new opportunities for differentiation and patient comfort.</li></ul> <p>More information are available on our dedicated page <a href="https://link.mediaoutreach.meltwater.com/ls/click?upn=u001.dGXcScUs4v-2FMAecsBUXk4cN4Y-2BUpe-2FDv8Tofj-2B2USWjiUR-2BAE-2Br9XxQ6811yLiVNleVzx40BOvkkJYMGEvM0LH-2BmiukPD3hueKYcSGwUvzuVyLk7tFPkxb0mKPDhUKpHsCE2bCxVTulTWGhNvKCGim-2BK5ELrSzbGZ9NNZdtIS-2BJxBKyMJhg-2BnehN4wY29r0RhNISALiw7NokGroVvJY4KKlOPyEXnvJPl-2F9TcVvFOlNKZK4mIntP2Rs03tlFJmR20yZ1hVpDj3GV6EjTBlQ89Q-3D-3Ddfd7_W9TbS1CN6YS-2FwqlpgWOZKXpfi8Zkj-2FqnrATmwh7Wmo9NZ9inv1AJS2oZAdu8T5SesISNh69hy-2Fgp2MIGgDD6wpCNsArCwSxt1mZxc9rUg6FMXHD67CAc2flZLmwep8oj7Bpb495MBEr4B4QPoruAtbBhcMCBYYd-2FFsOkJkQMQeBOGqsZjfuTSCQ4AazIc1TMwvWbkwcPIWf4N5h8vTUSP7xzJ7sQ2SwjYeQa39QE68BLrQrO5EzchvxMD5LMhj9jCv6quF8yFXE27YOnVRjzoSG1qtACzx-2F0o30lqo3Xt-2B7ElbPF3a9qMf2z1w1M0klOJ9d3NDn8ACv2b0d4iZjwlop6SF0gys9W9xBcWPCXFJJB4JDDQSoOYbJul3JB3ibi" target="_blank" rel="noreferrer noopener"><strong>here</strong></a>.</p> <p><strong>Chhanda Kapadia</strong>, Group Director, Technical Services, IMCD<strong> </strong>Pharmaceuticals, comments: <em>“Our presence at CPHI reflects our commitment to co-creating solutions that are not only innovative but also more sustainable and patient focused. They are a first-class example of our globally connected network of technical laboratories. We are looking forward to showcasing these innovations and engaging with partners and customers to explore how we can shape the future of healthcare together”.</em></p> <p>IMCD invites visitors to <strong>Booth 8.0S36 </strong>to meet its technical experts and explore how its tailored solutions can help bring better medicines to market.</p> <figure class="wp-block-image"><img decoding="async" src="https://meltwater-apps-production.s3.eu-west-1.amazonaws.com/uploads/images/565c32b917106f965e0c81b0/1761226804116/image_47551308841761226803983.jpg" alt="A person looking through a microscopeAI-generated content may be incorrect."/></figure> <p>IMCD Laboratory in Cologne, Germany (photo: IMCD)</p> <figure class="wp-block-image"><img decoding="async" src="https://meltwater-apps-production.s3.eu-west-1.amazonaws.com/uploads/images/565c32b917106f965e0c81b0/1761226804117/image_31700315551761226803987.jpg" alt="A room with tables and chairsAI-generated content may be incorrect."/></figure> <p>IMCD booth at CPHI Milan 2024 (photo: IMCD)</p>]]></content:encoded> </item> <item> <title>OMED Health Partners with Aviva to Support the Digestive Health of Employees</title> <link>https://international-biopharma.com/omed-health-partners-with-aviva-to-support-the-digestive-health-of-employees/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Thu, 23 Oct 2025 15:36:16 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=18202</guid> <description><![CDATA[OMED Health (“OMED”), a UK-based business pioneering non-invasive breath analysis for gut health and part of Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced a pilot as part of its longstanding collaboration with Aviva, the UK’s leading diversified insurer. The pilot, involving 75 Aviva […]]]></description> <content:encoded><![CDATA[<p></p> <ul class="wp-block-list"><li><em>75 Aviva employees to gain pilot access to doctor-led OMED Health Plans, which include the use of the OMED Health Breath Analyzer and mobile app</em></li> <li><em>Collaboration will evaluate the impact of the OMED solution on the digestive health and quality of life of participants in a workplace setting </em></li></ul> <p></p> <p>OMED Health (“OMED”), a UK-based business pioneering non-invasive breath analysis for gut health and part of Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy<sup>® </sup>for applications in early disease detection and precision medicine, today announced a pilot as part of its longstanding collaboration with Aviva, the UK’s leading diversified insurer.</p> <p>The pilot, involving 75 Aviva employees, intends to demonstrate the value of the OMED Health solution in a workplace setting by addressing the significant impact of gastrointestinal (GI) conditions on employee health and workplace productivity. The study is expected to be completed within six months.</p> <p>The pilot group of Aviva employees will receive access to OMED Health Plans<sup> 1</sup>, a CQC-registered service that guides individuals through personalized care pathways, including treatments and custom diet plans and supported by consultations with a licensed Owlstone medical doctor, to help them to gain control over their GI symptoms or conditions. Each participant will also receive an OMED Health Breath Analyzer, a handheld medical device that accurately measures gases related to the microbiome, and a linked mobile app<sup>2</sup> which collects vital symptom and dietary data. The Analyzer will be used to track progress through the pilot, and surveys will be provided to participants prior to and following the pilot to determine the direct impact of the Health Plan on their gut health and quality of life.</p> <p>Functional gut disorders such as Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methanogen Overgrowth (IMO), and food intolerances affect up to 1 in 8 people globally<sup>3</sup>, and in the UK alone 17% of adults have IBS or another form of GI disease<sup>4</sup>. Unfortunately, while there are many potential causes, symptoms can be non-specific and so many suffer for years without a clear resolution, impacting every aspect of normal life at home and at work.</p> <p>The broader implications of poor digestive health are significant. In the UK, direct costs of IBS alone are estimated at over £2 billion<sup>5</sup> per year with indirect costs twice this amount<sup>6</sup>. Gut health issues are also a leading cause of workplace absenteeism, with sufferers requiring almost twice as many days off work, and even when present average productivity is 30% lower<sup>6</sup>. Addressing these conditions by helping those living with digestive disease to find and fix their specific problems is therefore crucial both to support employees and to reduce the economic impact.</p> <p>This initiative strongly supports the “Fit for the Future: 10 Year Health Plan for England”<sup>7</sup>, which outlines three radical shifts for the NHS: from sickness to prevention, from analogue to digital, and from hospital to community. By improving employee health and reducing absenteeism, adoption of the OMED Health solution has the potential to contribute to the broader NHS ambition of enhancing productivity and supporting economic growth, while reducing the burden on the NHS by decreasing unnecessary visits to traditional healthcare settings through at-home diagnosis and management of disease.</p> <p>Aviva Ventures, Aviva Investors’ venture capital arm, first invested in Owlstone Medical in 2017, with Aviva Investors also having made an additional investment through its dedicated Venture & Growth Capital strategy, reflecting the company’s broader commitment to backing innovative technologies that improve health outcomes.</p> <p><strong>Ant Barker, Director of Venture Capital at Aviva Investors, commented:</strong> <em>“As well as being an investor in Owlstone, Aviva is committed to supporting the wellbeing of our employees and we’re pleased to offer this unique opportunity for our colleagues to play a role in medical developments. Digestive health issues can be incredibly disruptive, impacting daily life and professional performance, and so are gaining increased attention as part of employee wellness efforts. Owlstone’s innovative approach has the potential to transform how these conditions are understood and managed, and we’re excited to support their journey through this pilot initiative.”</em></p> <p><strong>Billy Boyle, co-founder and CEO at Owlstone Medical, said:</strong> <em>“OMED Health was founded to better the diagnosis and management of digestive health by providing patients and doctors with access to transformational breath-based solutions and clinical care, meaningfully improving patients’ quality of life, both at work and at home. We intend for the OMED solution to become part of the standard of care, either from ourselves or through license partners, and are grateful to Aviva for the support and funding provided for this study which will help us to advance towards this goal.”</em></p> <ol class="wp-block-list"><li><a href="https://omedhealth.com/our-treatments-services/" target="_blank" rel="noreferrer noopener">https://omedhealth.com/our-treatments-services/</a> </li> <li><a href="https://omedhealth.com/" target="_blank" rel="noreferrer noopener">https://omedhealth.com/</a></li> <li><a href="https://gutscharity.org.uk/advice-and-information/conditions/irritable-bowel-syndrome/" target="_blank" rel="noreferrer noopener">https://gutscharity.org.uk/advice-and-information/conditions/irritable-bowel-syndrome/</a></li> <li><a href="https://www.bjmp.org/content/irritable-bowel-syndrome-primary-care-physicians" target="_blank" rel="noreferrer noopener">https://www.bjmp.org/content/irritable-bowel-syndrome-primary-care-physicians</a></li> <li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6689327/" target="_blank" rel="noreferrer noopener">https://pmc.ncbi.nlm.nih.gov/articles/PMC6689327/</a></li> <li>Allergan IBS Global Impact Report</li> <li><a href="https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-future" target="_blank" rel="noreferrer noopener">https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-future</a></li></ol>]]></content:encoded> </item> <item> <title>Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays</title> <link>https://international-biopharma.com/biodesix-announces-expanded-bio-rad-laboratories-partnership-agreement-to-develop-droplet-digital-pcr-high-complexity-assays/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Thu, 23 Oct 2025 15:09:06 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=18200</guid> <description><![CDATA[Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing Biodesix, Inc., a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory submissions of in vitro diagnostic (IVD) assays to enable highly sensitive detection of […]]]></description> <content:encoded><![CDATA[<p></p> <p>Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing</p> <p>Biodesix, Inc., a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory submissions of <em>in vitro</em> diagnostic (IVD) assays to enable highly sensitive detection of multiple genomic markers focused on oncology applications, utilizing Bio-Rad’s Droplet Digital<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> PCR (ddPCR<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" />) technology on Bio-Rad’s QX600 platform. Following regulatory clearance, Biodesix will manufacture and distribute dedicated specimen collection kits for the developed assays.</p> <p>The first assays to be validated under the agreement include Bio-Rad’s ddPLEX ESR1 Mutation Detection Assay. ESR1 testing is becoming critical in HR+/HER2- advanced breast cancer due to the clinically demonstrated survival benefits from a new generation of therapy called oral selective estrogen receptor degraders (SERDs). The ddPLEX ESR1 Mutation assay will enable highly sensitive detection and absolute quantification of multiple ESR1 mutations from ctDNA samples.</p> <p>Once validated, the ESR1 assay will be offered as a test service at Biodesix’ accredited CLIA-CAP laboratory for biopharma customers to support the development of targeted therapeutics, as well as for clinical customers to support cancer treatment monitoring. Biodesix will also seek reimbursement for this assay through Centers for Medicare & Medicaid Services (CMS).</p> <p>“The emergence of ESR1 mutations as biomarkers for breast cancer has had a significant impact on the oncology market, leading to an increased global demand for rapid, sensitive assays,” <strong>said Scott Hutton, CEO, Biodesix.</strong> “We are proud to expand our partnership with Bio-Rad through this new agreement, demonstrating how our combined capabilities in mutation detection can address clinical needs with speed and precision, and opening doors to personalized, data-driven medicine.”</p> <p>“Through our long-standing relationship with Biodesix we have effectively delivered both clinical and research-based applications of our ddPCR technology for non-small cell lung cancer, as part of its Lung Diagnostics portfolio,” <strong>commented Steve Kulisch, VP Product Management, Life Science Group, Bio-Rad Laboratories. </strong>“Validation of our ddPLEX ESR1 kits will further expand our combined capabilities in clinical diagnostics, increasing access to sensitive biomarker detection for advanced breast cancer.”</p> <p>At the upcoming <a href="https://amp25.amp.org/" target="_blank" rel="noreferrer noopener">AMP conference, Nov 11-15, Boston, MA</a>, both companies will be providing more detail on their R&D visions, partnerships, and commercial roadmaps:</p> <ul class="wp-block-list"><li>Bio-Rad Laboratories <a href="https://amp25.amp.org/corporate-workshops/attend-a-corporate-workshop/" target="_blank" rel="noreferrer noopener">Corporate Workshop</a>, Nov 12, at 8 am</li> <li>Biodesix <a href="https://amp25.amp.org/corporate-workshops/attend-a-corporate-workshop/" target="_blank" rel="noreferrer noopener">Corporate Workshop</a>, Nov 12, at 4 pm</li></ul> <p><strong>About Biodesix</strong></p> <p>Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. <strong>Biodesix Diagnostic Tests</strong>, marketed as Nodify Lung<sup>®</sup> Nodule Risk Assessment and IQLung<sup>®</sup> Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. <strong>Biodesix Development Services</strong> enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit <a href="https://www.biodesix.com/" target="_blank" rel="noreferrer noopener">biodesix.com</a>.</p> <p><strong>Contacts:</strong></p> <p><strong>Media:</strong></p> <p>Natalie St. Denis, Director Corporate Communications, Biodesix</p> <p><a>natalie.stdenis@biodesix.com</a></p> <p>(720) 925-9285</p> <p>Zyme Communications (Bio-Rad PR firm)</p> <p>Dr. Maria Spyrou</p> <p>+44 (0) 7707 049 640</p> <p><a>maria.spyrou@zymecommunications.com</a></p> <p><strong>Investors:</strong></p> <p>Chris Brinzey, Partner, ICR</p> <p><a>chris.brinzey@icrhealthcare.com</a></p> <p>(339) 970-2843</p>]]></content:encoded> </item> <item> <title>ProImmune Expands into New 18,000 sq ft Global Headquarters Enabling Major Expansion in Immunology and Life Science Innovation</title> <link>https://international-biopharma.com/proimmune-expands-into-new-18000-sq-ft-global-headquarters-enabling-major-expansion-in-immunology-and-life-science-innovation/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Thu, 23 Oct 2025 12:49:52 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=18198</guid> <description><![CDATA[ProImmune Ltd, a global leader in life science reagents and services, today announced the opening of its new global headquarters building at Oasis Park, Oxford, enabling significant expansion of its operations and capacity to serve its global client base. Located within Oxford’s renowned bioscience and innovation ecosystem, the 70,000 sq ft Oasis Park is already […]]]></description> <content:encoded><![CDATA[<p></p> <ul class="wp-block-list"><li><em>Move follows ProImmune’s recent acquisition of Oasis Park a 70,000 sq ft Business and Light Industrial Park in Oxford, UK</em></li> <li><em>Increased operational capacity enables accelerated development of ProImmune’s REVEAL<sup>®</sup> Immunogenicity System and Ankyron<sup>®</sup> target binding technologies</em></li></ul> <p></p> <p>ProImmune Ltd, a global leader in life science reagents and services, today announced the opening of its new global headquarters building at Oasis Park, Oxford, enabling significant expansion of its operations and capacity to serve its global client base.</p> <p>Located within Oxford’s renowned bioscience and innovation ecosystem, the 70,000 sq ft Oasis Park is already home to six existing tenants. ProImmune’s new 18,000 sq ft main headquarters facility represents a substantial investment in state-of-the-art laboratories, providing ProImmune with the space and infrastructure to accelerate innovation in the REVEAL<sup>®</sup> Immunogenicity System, its suite of assay services to help understand immune responses to vaccines and therapeutic products, and the expansion of the Company’s revolutionary Ankyron<sup>®</sup> target binding reagent platform. Ankyrons are small, recombinant, target binding ankyrin repeat proteins, developed by ProImmune to overcome challenges in in antibody research. The high-specificity, sensitivity, and reproducibility of Ankyrons offers a cost-effective alternative to generating custom antibodies.</p> <p><em>“Our new global headquarters at Oasis Park, Oxford, are a reflection of ProImmune’s commitment to scientific excellence in immunology and global one-health biology,”</em> <strong>said Dr. Nikolai Schwabe, Chief Executive Officer of ProImmune</strong>. <em>“The investment into the park, and into our new flexible laboratory and office facilities, strengthens our ability to deliver world-class products and services, supporting our partners to develop safer and more effective therapies for patients around the world</em>.”</p>]]></content:encoded> </item> <item> <title>SGD Pharma presents new innovations at CPHI Frankfurt 2025, underscoring its leadership in sustainability and technological excellence</title> <link>https://international-biopharma.com/sgd-pharma-presents-new-innovations-at-cphi-frankfurt-2025-underscoring-its-leadership-in-sustainability-and-technological-excellence/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Thu, 23 Oct 2025 09:06:00 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=18196</guid> <description><![CDATA[SGD Pharma, a global leader in pharmaceutical glass primary packaging solutions, will showcase its enhanced portfolio of products and services at booth 8.0H24 during CPHI, taking place in Frankfurt, Germany, from 28th to 30rd October 2025. As part of the company’s strategic growth plan to expand its tubular glass offering in Europe, SGD Pharma has significantly reinforced its industrial and commercial […]]]></description> <content:encoded><![CDATA[<p></p> <p>SGD Pharma, a global leader in pharmaceutical glass primary packaging solutions, will showcase its enhanced portfolio of products and services at <strong>booth 8.0H24 </strong>during <strong>CPHI</strong>, taking place in Frankfurt, Germany, from <strong>28<sup>th</sup> to 30<sup>rd</sup> October 2025</strong>.</p> <p>As part of the company’s strategic growth plan to expand its tubular glass offering in Europe, SGD Pharma has significantly reinforced its industrial and commercial footprint with the acquisition of Alphial S.r.l, a tubular glass converting company manufacturing ampoules, vials and Ready to Use (RTU) products. This move positions SGD Pharma as a key player in the tubular segment as well as its leadership in molded, enabling greater responsiveness, increased capacity, and innovation tailored to the evolving needs of the European pharma market. The acquisition of Alphial will ideally complement the company’s existing operations in Europe and tubular facility in Vemula, India, recently bolstered by a joint venture with Corning. Alphial will also be attending CPHI, find out more about how the expansion is reshaping tubular glass packaging at booth 8.0G1.</p> <p>New for CPHI 2025, SGD Pharma continues to lead with its flagship <strong>Sealian</strong> platform. This internal surface treatment for molded glass vials creates a strong barrier coating that protects sensitive therapeutics, improves chemical durability (especially against alkaline solutions), and reduces interactions between drug products and packaging. Sealian is available in clear and amber glass for vial sizes, ranging from <strong>3 ml to 500 ml</strong> and is suited for every route of administration (parenteral, oral, nasal).</p> <p>Also on display at CPHI 2025:</p> <ul class="wp-block-list"><li><strong>IDENCY</strong>: now fully completed range of vials in <strong>6 ml, 10 ml and 20 ml</strong>, combining the chemical and mechanical resistance of molded glass with external dimensions comparable with standard tubular glass for fill & finish lines.</li> <li><strong>Sterinity EZ-fill<sup>®</sup></strong>: SG EZ-Fill’s ready-to-use (RTU) molded glass vials, offering sterile, flexible and high-quality solutions.</li> <li><strong>Ensiemo</strong>: the full pharma-grade Type III vial and pipette packaging system, now available with tamper-evident and child-resistant caps.</li> <li><strong>Velocity<sup>®</sup> Vials</strong>: SGD Pharma’s Type I tubular glass vials with external low-friction coating from Corning, designed to optimize fill & finish operations — reducing friction, improving throughput (20‑50 % efficiency gains), lowering particulate generation by up to 96 %.</li></ul> <p>Newly at CPHI, SGD Pharma also introduces <strong>Proseal+</strong>, an advanced external treatment for molded and tubular vials that enhances moisture and oxygen protection to extend shelf life of pharmaceutical contents.</p> <p><br>Further strengthening its service offering, SGD Pharma’s newly launched <strong>Lab Services</strong> are fully operational, delivering analytical testing to pharma/biopharma companies, CMOs/CDMOs, and other glass packaging players. More expansions to the Lab Services offering are expected in 2026.</p> <p>Regarding its latest sustainable initiatives, SGD Pharma has updated its emissions targets: compared to 2022 levels, the company is targeting a <strong>42 % reduction by 2030</strong> and <strong>65 % by 2040</strong>. The group has been awarded <strong>Platinum status by EcoVadis in 2025</strong>, reflecting top-tier ESG performance among glass manufacturers.</p> <p>Olivier Rousseau, CEO of SGD Pharma states:</p> <p><em>“At CPHI 2025, we are proud to mark a major milestone in our growth strategy with the acquisition of Alphial. This integration strengthens our industrial footprint across Europe and supports our ambition to expand our offering to better serve the evolving needs of our pharmaceutical partners, in flexibility, safety, and speed. From Sealian to Velocity, every innovation also reflects our strong commitment to sustainability.”</em></p> <p>Visit us at <strong>booth 8.0H24 </strong>to see these innovations in person and learn how SGD Pharma can support your requirements while raising the bar for performance and sustainability.</p>]]></content:encoded> </item> <item> <title>Enamine contributes to the discovery of promising broad-spectrum coronavirus antiviral</title> <link>https://international-biopharma.com/enamine-contributes-to-the-discovery-of-promising-broad-spectrum-coronavirus-antiviral/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Thu, 23 Oct 2025 08:54:26 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=18194</guid> <description><![CDATA[Enamine, a leading chemistry and R&D services company, today announced that it was a key synthetic chemistry contributor to a first-of-its-kind, open-science approach that led to the development of a promising broad-spectrum coronavirus antiviral pre-clinical candidate. Enamine’s chemistry platform delivered over 2,000 new compounds during the early stages of the programme that resulted in the discovery of […]]]></description> <content:encoded><![CDATA[<p></p> <ul class="wp-block-list"><li><em>Open-science research initiative, COVID Moonshot and the AI-driven Structure-enabled Antiviral Platform (ASAP) consortium, delivered a promising pre-clinical candidate </em></li> <li><em>2,000 new compounds generated for the programme are now available from Enamine’s catalogue</em></li></ul> <p></p> <p>Enamine, a leading chemistry and R&D services company, today announced that it was a key synthetic chemistry contributor to a first-of-its-kind, open-science approach that led to the development of a promising broad-spectrum coronavirus antiviral pre-clinical candidate. Enamine’s chemistry platform delivered over 2,000 new compounds during the early stages of the programme that resulted in the discovery of pre-clinical candidate ASAP-0017445. The candidate is designed to be a direct-to-generic, globally accessible treatment ready for future coronavirus pandemics.</p> <p>The pre-clinical drug candidate ASAP-0017445, which exhibited encouraging preliminary safety and efficacy results, was recently nominated by Drugs for Neglected Diseases initiative (DNDi), a non-profit medical research organisation, as a highly effective antiviral for coronaviruses<sup>[1]</sup>. The drug was developed by the COVID Moonshot and ASAP (AI-driven Structure-enabled Antiviral Platform) Discovery Consortium, formed during the COVID-19 pandemic, of which Enamine is a member from the early days. The consortia aimed to accelerate open-science antiviral drug discovery and deliver oral antivirals to prevent future pandemics. Enamine played a pivotal role in the early stages of the COVID Moonshot programme, enabling rapid production of novel molecules, compound management, and logistics, which significantly accelerated the discovery cycle. The Company also performed Tier 1 ADME tests in close proximity to the compound depository, which was essential in shortening Design-Make-Test-Analyse cycles. Further optimisation of the lead series of compounds produced by Enamine was conducted by MedChemica, resulting in the development of ASAP-0017445<em>.</em></p> <p>“<em>We are proud to have been a part of this groundbreaking open science collaboration, where researchers from across the world have come together to advance vital drug discovery efforts. We are grateful to all the other organisations who played a part in contributing to the global effort to strengthen resilience against future pandemics,</em>” <strong>said Vladimir Ivanov, Executive Vice President of Enamine.</strong></p> <p>The structure of ASAP-0017445 was publicly disclosed in March 2025<sup>[2]</sup>. The patent<sup>[3]</sup> and all data generated during the compound’s development have recently been published to support the open science approach. All 2,000 compounds generated during this collaboration are now available from Enamine’s catalogue.</p> <p><strong>References:</strong></p> <p>[1] – <a href="https://dndi.org/press-releases/2025/open-science-approach-delivers-preclinical-candidate-broad-spectrum-coronavirus-antiviral/" target="_blank" rel="noreferrer noopener">Open-science approach delivers a promising pre-clinical candidate for broad-spectrum coronavirus antiviral | DNDi</a></p> <p>[2] – <a href="https://cen.acs.org/acs-news/acs-meeting-news/Antiviral-unveiled-goes-multiple-coronaviruses/103/web/2025/03" target="_blank" rel="noreferrer noopener">https://cen.acs.org/acs-news/acs-meeting-news/Antiviral-unveiled-goes-multiple-coronaviruses/103/web/2025/03</a></p> <p>[3] – <a href="https://patentscope.wipo.int/search/en/WO2025125695" target="_blank" rel="noreferrer noopener">https://patentscope.wipo.int/search/en/WO2025125695</a></p>]]></content:encoded> </item> <item> <title>Bruker Announces FDA Clearance of Claims 7 and 8 for theMALDI Biotyper® CA System, Expanding Diagnostic Capabilities</title> <link>https://international-biopharma.com/bruker-announces-fda-clearance-of-claims-7-and-8-for-themaldi-biotyper-ca-system-expanding-diagnostic-capabilities/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Mon, 20 Oct 2025 12:25:22 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=18189</guid> <description><![CDATA[At the annual IDWeek meeting (https://idweek.org/), Bruker announced the U.S. Food and Drug Administration (FDA) clearance of Claim 7 and Claim 8 for its MALDI Biotyper® CA System, marking a significant advancement in clinical microbial identification capabilities. The clearance includes the MBT Compass HT CA software and MBT FAST™ Shuttle US IVD (Claim 7), as well as a major expansion of the […]]]></description> <content:encoded><![CDATA[<p></p> <ul class="wp-block-list"><li><strong><em>Claim 7: FDA clearance of MBT FAST<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Shuttle US IVD and MBT Compass HT CA software improves workflow efficiency and accelerates data processing.</em></strong></li> <li><strong><em>Claim 8: FDA approval of expanded reference library increases coverage to 549 validated microbial species.</em></strong></li></ul> <p></p> <p>At the annual <strong>ID</strong>Week meeting (<a href="https://idweek.org/" target="_blank" rel="noreferrer noopener">https://idweek.org/</a>), Bruker announced the U.S. Food and Drug Administration (FDA) clearance of Claim 7 and Claim 8 for its <strong>MALDI Biotyper<sup>®</sup> CA System</strong>, marking a significant advancement in clinical microbial identification capabilities. The clearance includes the <strong>MBT Compass HT CA</strong> software and <strong>MBT FAST<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Shuttle US IVD</strong> (Claim 7), as well as a major expansion of the FDA-cleared reference library (Claim 8), now encompassing 549 clinically validated microbial species across gram-positive and gram-negative bacteria, anaerobes and yeasts.</p> <p><strong>Technology Enhancements</strong></p> <p> The MALDI Biotyper CA System is a mass spectrometry-based platform that uses MALDI-TOF technology for rapid identification of microorganisms following culture from human specimens, either from isolated colonies or positively flagged blood cultures. With the newly cleared MBT Compass HT CA software, laboratories benefit from enhanced performance, including parallel data processing, improved user management, and support for 21 CFR Part 11 compliance. It also features IDealTune, an automated tuning function that maintains optimal system performance by continuously monitoring the US IVD Bacterial Test Standard quality control results. This reduces the need for manual tune-ups and ensures consistent diagnostic reliability over extended periods.</p> <p>The MBT FAST Shuttle US IVD enables accelerated drying of droplets, including MALDI matrix, hence significantly reducing sample preparation time as compared to room temperature drying. In addition to speed, it also standardizes sample preparation, resulting in reproducible matrix crystallization – a critical factor in MALDI-TOF analysis. This consistency further improves sample preparation quality which can contribute to more reliable and accurate identification results.</p> <p><strong>Expanded Diagnostic Reach</strong></p> <p> The FDA-cleared reference library now includes reference spectra of 549 clinically validated microbial species in 437 groups, covering gram-positive and gram-negative bacteria, anaerobes, and yeasts. Additionally, the system includes over 3400 non-clinically validated species, which are clearly marked in reports to guide alternate identification methods. These results are not transmitted to the laboratory information system, ensuring clarity and compliance in reporting.</p> <p><strong>Outlook</strong></p> <p>Looking ahead, Bruker is finalizing internal processes to prepare for shipment of the updated MALDI Biotyper CA System in the U.S. and Puerto Rico. In addition to new system deliveries, current users of the MALDI Biotyper CA System can also benefit from the newly FDA-cleared features – the updated reference library, MBT FAST Shuttle US IVD, and MBT Compass HT CA software – to expand the capabilities of their existing systems. The company continues to invest in expanding its validated library and software capabilities, with future claims expected to further enhance diagnostic reach and efficiency.</p> <figure class="wp-block-image size-full"><img fetchpriority="high" decoding="async" width="332" height="513" src="https://international-biopharma.com/wp-content/uploads/2025/10/MALDI-Biotyper-sirius-CA-system.png" alt="" class="wp-image-18190" srcset="https://international-biopharma.com/wp-content/uploads/2025/10/MALDI-Biotyper-sirius-CA-system.png 332w, https://international-biopharma.com/wp-content/uploads/2025/10/MALDI-Biotyper-sirius-CA-system-194x300.png 194w" sizes="(max-width: 332px) 100vw, 332px" /></figure> <figure class="wp-block-image size-full"><img decoding="async" width="379" height="290" src="https://international-biopharma.com/wp-content/uploads/2025/10/MBT-FAST-Shuttle-US-IVD.png" alt="" class="wp-image-18191" srcset="https://international-biopharma.com/wp-content/uploads/2025/10/MBT-FAST-Shuttle-US-IVD.png 379w, https://international-biopharma.com/wp-content/uploads/2025/10/MBT-FAST-Shuttle-US-IVD-300x230.png 300w" sizes="(max-width: 379px) 100vw, 379px" /></figure>]]></content:encoded> </item> <item> <title>Cyclana Bio Raises £5M to Advance Drug Discovery for Endometriosis</title> <link>https://international-biopharma.com/cyclana-bio-raises-5m-to-advance-drug-discovery-for-endometriosis/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Mon, 20 Oct 2025 09:30:34 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=18182</guid> <description><![CDATA[Cyclana Bio, a biotechnology company pioneering tissue-level approaches to women’s health, today announced the close of a £5M pre-seed funding round, co-led by NfX and Eka VC, and including Cocoa VC, Wilbe, and Angel investors. The investment will enable Cyclana Bio to develop functional disease models and its platform, dedicated to revolutionising women’s health through tissue […]]]></description> <content:encoded><![CDATA[<p></p> <ul class="wp-block-list"><li><em>Co-led by NfX and Eka VC, investors include Cocoa VC, Wilbe, and Angel investors</em></li> <li><em>Investment will support development of whole tissue-based platform for identification of druggable targets and scaling of observational clinical trial</em></li></ul> <p></p> <p>Cyclana Bio, a biotechnology company pioneering tissue-level approaches to women’s health, today announced the close of a £5M pre-seed funding round, co-led by NfX and Eka VC, and including Cocoa VC, Wilbe, and Angel investors. The investment will enable Cyclana Bio to develop functional disease models and its platform, dedicated to revolutionising women’s health through tissue level therapeutics, starting with the discovery of treatments for endometriosis.</p> <p>Endometriosis is a chronic and debilitating lifelong condition that affects 1 in 10 women worldwide. Despite its prevalence, the disease physiology of endometriosis remains poorly understood and treatment options remain limited. Cyclana Bio is addressing a need to better serve millions of women by developing physiologically relevant models and utilising AI-driven multi-scale data integration to enable the discovery of druggable targets to improve treatment outcomes.</p> <p>Cyclana Bio has demonstrated the role of the extracellular matrix (ECM) in endometriosis, where dysregulation of the ECM causes inflammation and loss of tissue function. Until now, drug development strategies to treat endometriosis have focused on intracellular mechanisms, failing to target the interaction between cells and the ECM, and have resulted in sub-optimal treatment efficacy. The Company is focused on building whole tissue models of disease, harnessing menstrual fluid, received from donations from an observational clinical trial, and lab-based modelling to uncover early biomarkers of disease and identify novel targets for drug development. Initially focused on endometriosis, Cyclana Bio’s whole tissue-based methodology represents a promising approach to address other underserved chronic inflammatory diseases that share similar tissue-level mechanisms.</p> <p><em>“Our mission at Cyclana is not just to close the gender health gap but propel women to the forefront of drug discovery. We are redefining how therapies are developed, starting with the basic science, by zooming out and studying disease at the level where it truly emerges: the tissue itself,”</em><strong> said Dr. Léa Wenger, CEO and Co-Founder of Cyclana Bio. </strong><em>“By raising venture capital as our first source of financing, we are building a model with the consumer, the patient, at the centre. We now have not only the privilege but also the responsibility to generate the best pipeline to bring new treatments to the</em> <em>clinic.”</em></p> <p><em>“Our goal is not just to develop new treatments, but to change the framework of biomedical discovery itself,” </em><strong>Prof. Kevin Chalut, CSO and Co-Founder, Cyclana Bio, added. </strong><em>“By starting with women’s health, we’re addressing one of the greatest unmet needs in medicine. In doing so, we will not only cure a debilitating disease many women suffer from, we will also set the stage for a broader transformation in how we understand and treat chronic disease.”</em></p>]]></content:encoded> </item> <item> <title>OpenEvidence and Veeva Announce Open Vista Partnership</title> <link>https://international-biopharma.com/openevidence-and-veeva-announce-open-vista-partnership/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Thu, 16 Oct 2025 15:27:27 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=18180</guid> <description><![CDATA[Veeva Systems and OpenEvidence today announced the formation of a long-term partnership to jointly create and market Open Vista. Open Vista will use AI to increase patient access to clinical trials, accelerate drug discovery through better understanding of unmet needs, and improve understanding and adoption of existing approved medicines to provide better patient outcomes. “OpenEvidence has become […]]]></description> <content:encoded><![CDATA[<p></p> <p><a href="https://www.veeva.com/" target="_blank" rel="noreferrer noopener">Veeva Systems</a> and <a href="https://www.openevidence.com/" target="_blank" rel="noreferrer noopener">OpenEvidence</a> today announced the formation of a long-term partnership to jointly create and market Open Vista. Open Vista will use AI to increase patient access to clinical trials, accelerate drug discovery through better understanding of unmet needs, and improve understanding and adoption of existing approved medicines to provide better patient outcomes.</p> <p>“OpenEvidence has become an accelerator for the dissemination of medical knowledge, with more than 40% of U.S. physicians actively using its point-of-care clinical decision support AI. By bridging the gap between peer-reviewed evidence and on-the-ground medical practice, OpenEvidence is streamlining and quickening the translation of medical research from bench to bedside,” said Daniel Nadler, CEO of OpenEvidence. “For many patients with serious illnesses who have exhausted first and second line therapies, clinical trials are their most promising form of healthcare. In partnering with Veeva, we now have a unique opportunity to go a step further and leverage the power of AI to connect physicians and patients to relevant clinical trials and cutting-edge therapies.”</p> <p>“We are very excited about our long-term partnership with OpenEvidence as we enter the AI chapter in life sciences,” said Veeva CEO Peter Gassner. “Combining the strengths of Veeva and OpenEvidence, we can use AI to bridge life sciences companies making life-saving medicines, patients, and the physicians who treat them. With Open Vista our aim is to help life sciences companies accelerate the development of effective new treatments, enable more patients to participate in clinical trials, and advance the understanding and adoption of existing medicines for better patient outcomes.”</p> <p>The first Open Vista product offerings are expected to be released in 2026.</p> <p><strong>About Veeva Systems<a></a></strong></p> <p>Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a <a href="https://www.veeva.com/pbc/" target="_blank" rel="noreferrer noopener">Public Benefit Corporation</a>, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit <a href="http://veeva.com/" target="_blank" rel="noreferrer noopener">veeva.com</a>.</p> <p><strong>About OpenEvidence</strong></p> <p><a href="https://www.openevidence.com/" target="_blank" rel="noreferrer noopener">OpenEvidence</a> is the fastest-growing clinical decision support platform in the United States, and the most widely used medical search engine among U.S. clinicians. OpenEvidence is trusted by hundreds of thousands of verified healthcare professionals to make high-stakes clinical decisions at the point of care that are sourced, cited, and grounded in peer-reviewed medical literature. Founded with the mission to organize and expand global medical knowledge, Open Evidence is actively used by more than 10,000 hospitals and medical centers and by over 40% of physicians in the United States.</p> <p><strong>Veeva Forward-Looking Statements</strong></p> <p>This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2025, which you can find <em><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1393052/000139305225000067/veev-20250731.htm#i7e129a0ad48d459ea13c21cd7e2de073_124" target="_blank" rel="noreferrer noopener">here</a></em> (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at <em><a href="https://www.sec.gov/" target="_blank" rel="noreferrer noopener">sec.gov</a></em>.</p>]]></content:encoded> </item> <item> <title>Alithea Genomics Introduces MERCURIUS™ Spheroid DRUG-seq: Extraction-Free, RNA-seq for 3D Drug Screening and Toxicology</title> <link>https://international-biopharma.com/alithea-genomics-introduces-mercurius-spheroid-drug-seq-extraction-free-rna-seq-for-3d-drug-screening-and-toxicology/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Thu, 16 Oct 2025 10:55:56 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=18176</guid> <description><![CDATA[Alithea Genomics, a leader in next-generation transcriptomic solutions, today announced the commercial launch of MERCURIUS™ Spheroid DRUG-seq, a novel, extraction-free RNA sequencing library preparation kit built for 3D spheroid models. This advancement extends Alithea’s MERCURIUS DRUG-seq technology into physiologically relevant 3D systems, bringing simplicity, sensitivity, and throughput to drug screening in more in vivo–like cellular environments. With MERCURIUS™ Spheroid DRUG-seq, […]]]></description> <content:encoded><![CDATA[<p></p> <p>Alithea Genomics, a leader in next-generation transcriptomic solutions, today announced the commercial launch of <a href="https://biostratamarketing.acemlnb.com/lt.php?x=4lZy~GE2V3DK6H37__xNUxJu1HApjd9zvPgyY5PDJaSfDXz.y0y7x.F03X4Rzk~w_x6zXXLMJ4Gf553-2NxFV.C-1nApk_D" target="_blank" rel="noreferrer noopener">MERCURIUS<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Spheroid DRUG-seq</a>, a novel, extraction-free RNA sequencing library preparation kit built for 3D spheroid models. This advancement extends Alithea’s <a href="https://biostratamarketing.acemlnb.com/lt.php?x=4lZy~GE2V3DK6H37__xNUxJu1HApjd9zvPgyY5PDJaSfDXz.y0y7x.F03X4Rzk~w_x6zXXLMJ4Gf553-2NxFV.C-1nApk_H" target="_blank" rel="noreferrer noopener">MERCURIUS DRUG-seq</a> technology into physiologically relevant 3D systems, bringing simplicity, sensitivity, and throughput to drug screening in more <em>in vivo</em>–like cellular environments.</p> <p>With <strong>MERCURIUS<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Spheroid DRUG-seq</strong>, researchers can bypass conventional RNA extraction and pre-amplification, enabling direct processing of spheroids in an optimized lysis buffer. The streamlined, one-day workflow delivers full transcriptome coverage in a massively multiplexed manner, making the method ideal for large-scale mechanistic and toxicity studies in 3D models.</p> <p>MERCURIUS<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Spheroid DRUG-seq successfully detected ><strong>14,000 genes per sample</strong> at ~1.7 million reads and is compatible with Illumina and AVITI sequencers (with broader compatibility upon request).</p> <p><em>“MERCURIUS<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Spheroid DRUG-seq follows our strong belief that 3D biology deserves transcriptomic profiling at scale. We can now bring full transcriptome insights into spheroid models without sacrificing throughput or simplicity,” </em>said Riccardo Dainese CEO and Co-founder of Alithea Genomics. <em>“We believe this tool will unlock new layers of transcriptomic discovery in drug screening and toxicology, enabling researchers to explore disease biology in architectures far closer to human tissue.”<br></em><br>Researchers and industry professionals are invited to visit <strong>Alithea Genomics at ASHG (Boston)</strong> and <strong>ELRIG (Liverpool)</strong> to see live demonstrations of the Spheroid DRUG-seq workflow and discuss use cases across 3D drug screening, toxicity assessment, and functional genomics.</p> <p>Alithea Genomics is now accepting orders for both the kits and the services.</p> <p><strong>About RNA-seq in 3D Models and Organoids</strong><br>Organoid and spheroid culture systems recapitulate key structural and functional features of <em>in vivo</em> tissues, making them powerful models for drug discovery and toxicology. However, conventional RNA-seq workflows often struggle with the complexity of 3D matrices, limited sample input, and RNA extraction challenges. MERCURIUS<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Spheroid DRUG-seq addresses these bottlenecks by providing a high-throughput RNA-seq solution tailored for spheroids and organoids.</p> <p><strong>About Alithea Genomics</strong><br>Alithea Genomics empowers researchers in biotech, pharma, and academic settings with massively parallel, affordable transcriptomic technologies. Its MERCURIUS<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> DRUG-seq, BRB-seq and FLASH-seq platforms enable efficient, high-sensitivity RNA profiling across bulk samples, single cells and now 3D systems. Founded in 2020 at EPFL (Lausanne, Switzerland), Alithea continues to expand its global footprint with offices in Europe and North America.</p> <p><strong>Media Contact</strong><br>Riccardo Dainese<br>Alithea Genomics<br>+ 41 788 30 31 39<br><a href="mailto:info@alitheagenomics.com">info@alitheagenomics.com</a><br><a href="https://biostratamarketing.acemlnb.com/lt.php?x=4lZy~GE2V3DK6H37__xNUxJu1HApjd9zvPgyY5PDJaSfDXz.y0y7x.F03X4Rzk~w_x6zXXLMJ4Gf553-2NxFV.C-1nApk_P" target="_blank" rel="noreferrer noopener">https://alitheagenomics.com</a></p>]]></content:encoded> </item> </channel></rss> If you would like to create a banner that links to this page (i.e. this validation result), do the following:
Download the "valid RSS" banner.
Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)
Add this HTML to your page (change the image src attribute if necessary):
If you would like to create a text link instead, here is the URL you can use:
http://www.feedvalidator.org/check.cgi?url=https%3A//international-biopharma.com/feed/
